This undated handout photo provided by Gilead Sciences shows the Hepatitis-C medication Sovaldi. A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis-C pills combined, according to new data from IMS Health.  (AP Photo/Gilead Sciences)

WASHINGTON (AP) — The price may be high but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.

Read the rest of this entry »

Tags: , , , , , , , , , , , , , , , ,